New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
09:02 EDTAEZSAeterna Zentaris upgraded to Buy from Hold at MLV Equity
MLV Equity believes Aeterna Zentaris' pipeline drugs, AEZS-108 and AEZS-130, have substantial value and that DSMB recommendation on Perifosine in Q1 could act as a catalysts. Price target is $5.50.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
09:15 EDTAEZSOn The Fly: Pre-market Movers
HIGHER: Anavex Life Sciences (AVXL), up 20.5% after 3-71 data published in Neurodegenerative Diseases... Oramed Pharmaceuticals (ORMP), up 16.7% after signing up to $50M licensing and investment agreements for insulin in China... Horizon Pharma (HZNP), up 3.8% after receiving EC approval for Ravicti... Fitbit (FIT), up 4.2% after being upgraded to Overweight from Equal Weight at Barclays... Sarepta Therapeutics (SRPT), up 1.6% following a positive mention by Barron's. LOWER: Cyclacel Pharmaceuticals (CYCC) and AEterna Zentaris (AEZS), down 24.5% and 13.6%, respectively, following a Tweet by KaloBios (KBIO) CEO Martin Shkreli... Supercom (SPBC), down 21.6% after reporting preliminary third quarter revenue... Macrocure (MCUR), down 11.5% after announcing that the company's CFO and Chief Medical Officer are stepping down... lululemon (LULU), down 4.4% after being downgraded to Underperform from Market Perform at FBR Capital... Office Depot (ODP), down 2.8% after the NY Post reported that regulators are preparing to block Staples' (SPLS) proposed acquisition of Office Depot... SouFun (SFUN), down 2% after being downgraded to Neutral from Buy at Goldman.
08:59 EDTAEZSCyclacel Pharmaceuticals, Aeterna Zentaris 'worthless,' says Shkreli
Martin Shkreli, the CEO KaloBios (KBIO) and Turing Pharma, said in a tweet that Cyclacel Pharmaceuticals (CYCC) and Aeterna Zentaris (AEZS) shares are "worthless." Shares of both stocks are indicated lower this morning following Shkreli's Twitter post. Reference Link
November 25, 2015
13:11 EDTAEZSAeterna Zentaris CEO responds to recent developments, says fundamentals 'strong'
Aeterna Zentaris chairman and CEO David Dodd released a statement seeking to provide clarity on what he called recent "corporate developments." Dodd said, "Yesterday's announcement regarding corporate developments, which was required by IIROC on behalf of the Toronto Stock Exchange, caused some to question the fundamentals of our business. I want to reiterate that we believe the fundamentals remain strong. We have two products in Phase 3. One of the products, Zoptrex, is in the late stage of Phase 3. We instituted a confirmatory Phase 3 clinical trial of Macrilen after a panel of U.S. and EU endocrinology experts advised us to continue to seek approval for the compound because of their confidence in its efficacy and because there currently is no FDA-approved diagnostic test for adult growth hormone deficiency. That Phase 3 study recently enrolled its first patient, keeping us on track to conclude it by the end of 2016... We continue discussions with others about adding to our portfolio of promoted products and about the commercial rights to and development of Zoptrex in markets outside the United States."
November 24, 2015
12:59 EDTAEZSGEO Investing says Aeterna Zentaris rally 'totally unwarranted'
GEO Investing tweeted, "We believe $AEZS pump is totally unwarranted and that stock will quickly follow if $KBIO sells off."
11:30 EDTAEZSAeterna Zentaris says no corporate developments to account for stock movement
Aeterna Zentaris, at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release there are no corporate developments that would cause the recent movements in the company's share price.
November 19, 2015
08:32 EDTAEZSAeterna Zentaris enrolls first patient for Phase 3 trial of Macrilen
Aeterna Zentaris has enrolled the first patient for its confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. Based on meetings with the FDA as well as the EMA and subsequent written scientific advice, the company believes that the study meets the FDA's and the EMA's study-design expectations allowing US and European approval, if successful.
November 18, 2015
08:34 EDTAEZSAeterna Zentaris announces share consolidation details for NASDAQ compliance
Subscribe for More Information
November 16, 2015
11:52 EDTAEZSAeterna Zentaris announces shareholder approval of 100-for-1 share consolidation
Aeterna Zentaris announced that the holders of its issued and outstanding common shares approved a share consolidation and that the company has determined that the consolidation ratio will be 100-for-1. The company intends to implement the consolidation in the coming days and will shortly provide all relevant details regarding the consolidation, including its effective date and the date on which the common shares are expected to commence trading on a post-consolidation basis on the NASDAQ Capital Market and the Toronto Stock Exchange and information for registered and beneficial shareholders to exchange their pre-consolidation for post-consolidation common shares. The company also announces that Marcel Aubut is no longer a member of the Board of Directors effective November 16.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use